ライフサイエンスコーパス: cardiopulmonary bypass

1 ct to treatment assignment (OPCAB or CABG on cardiopulmonary bypass).

2 lving inflammatory response during and after cardiopulmonary bypass.

3 mean arterial blood pressure targets during cardiopulmonary bypass.

4 extraction, early after cardiac surgery with cardiopulmonary bypass.

5 infants undergoing surgery with and without cardiopulmonary bypass.

6 ngenital heart disease both with and without cardiopulmonary bypass.

7 similar rates after surgery with or without cardiopulmonary bypass.

8 ily on methods of vital organ support during cardiopulmonary bypass.

9 to 36 months of age, undergoing surgery with cardiopulmonary bypass.

10 al circulatory arrest or continuous low-flow cardiopulmonary bypass.

11 e elective, and almost all patients required cardiopulmonary bypass.

12 al management strategies for separation from cardiopulmonary bypass.

13 in in group B was 104 +/- 160 at 4 hrs after cardiopulmonary bypass.

14 from cardiopulmonary bypass or use to avoid cardiopulmonary bypass.

15 ples before and after the ischemic insult of cardiopulmonary bypass.

16 ed management of cerebral oxygenation during cardiopulmonary bypass.

17 rSo(2) during the 60-minute period following cardiopulmonary bypass.

18 evels decrease in infants and children after cardiopulmonary bypass.

19 25 at 4, 24, and 48 hrs, respectively, after cardiopulmonary bypass.

20 s to achieve separation from or avoidance of cardiopulmonary bypass.

21 an 2 years old undergoing heart surgery with cardiopulmonary bypass.

22 with group B before and 24 and 48 hrs after cardiopulmonary bypass.

23 deep hypothermic circulatory arrest or even cardiopulmonary bypass.

24 an their racial counterparts who had CABG on cardiopulmonary bypass.

25 e undergoing cardiac surgery with the use of cardiopulmonary bypass.

26 al echocardiography, cardiac surgery, and/or cardiopulmonary bypass.

27 ms obtained during initiation and weaning of cardiopulmonary bypass.

28 ll with cardiac arrest and longer periods of cardiopulmonary bypass.

29 yocardial arrest and reperfusion achieved by cardiopulmonary bypass.

30 ine after CABG is not specific to the use of cardiopulmonary bypass.

31 preservation, followed by resuscitation with cardiopulmonary bypass.

32 after the induction of anesthesia and before cardiopulmonary bypass.

33 heart valve interventions without the use of cardiopulmonary bypass.

34 o attenuate the coagulopathy associated with cardiopulmonary bypass.

35 ollowed by 20 mins of EPR using miniaturized cardiopulmonary bypass.

36 ary revascularization without utilization of cardiopulmonary bypass.

37 ith all-out resuscitation, usually requiring cardiopulmonary bypass.

38 elations during initiation and conclusion of cardiopulmonary bypass.

39 d in all groups by a 2-hour resuscitation by cardiopulmonary bypass.

40 ithout consequent pulmonary regurgitation or cardiopulmonary bypass.

41 s in reducing bleeding and transfusion after cardiopulmonary bypass.

42 following elective cardiac surgery requiring cardiopulmonary bypass.

43 other short-term outcomes compared with CABG-cardiopulmonary bypass.

44 mals following ischemia and reperfusion with cardiopulmonary bypass.

45 e undergoing cardiac surgery with the use of cardiopulmonary bypass.

46 patients who underwent cardiac surgery with cardiopulmonary bypass.

47 hours, and 18-24 hours after separation from cardiopulmonary bypass.

48 nction in patients after cardiac surgery and cardiopulmonary bypass.

49 verse events after cardiac surgery requiring cardiopulmonary bypass.

50 h risk of morbidity and mortality undergoing cardiopulmonary bypass.

51 rdiopulmonary physiology and the sequelae of cardiopulmonary bypass.

52 rombocytopenic and have cardiac surgery with cardiopulmonary bypass.

53 f methylprednisolone for patients undergoing cardiopulmonary bypass.

54 r major morbidity after cardiac surgery with cardiopulmonary bypass.

55 h risk of morbidity and mortality undergoing cardiopulmonary bypass.

56 frequently occur after cardiac surgery with cardiopulmonary bypass.

57 were hemodynamically stable with no need for cardiopulmonary bypass.

58 in patients undergoing cardiac surgery with cardiopulmonary bypass.

59 d lower in the sepsis group during and after cardiopulmonary bypass.

60 on to conventional surgery (0.6%) and use of cardiopulmonary bypass (0.7%) were rare.

61 The overall rate of LOF was 4.3% (return to cardiopulmonary bypass, 2.6%; intraaortic balloon pumps,

62 3) and during the 60-minute period following cardiopulmonary bypass (65+/-11% versus 75+/-10%, P=0.00

63 rSo(2) from postinduction to 60 minutes post cardiopulmonary bypass (71+/-10% versus 78+/-6%, P=0.01)

64 ion harvesting (98.9%, 66.0%, and 68.1%) and cardiopulmonary bypass (83.4%, 45%, and 36.9%) were less

65 Right atrial biopsies were collected before cardiopulmonary bypass and 10 minutes after aortic cross

66 Blood samples were collected before cardiopulmonary bypass and 4, 24, and 48 hrs after cardi

67 pg/mL) for all patients was 21 +/- 63 before cardiopulmonary bypass and 80 +/- 145, 43 +/- 79, and 19

68 y been well tolerated in patients undergoing cardiopulmonary bypass and abdominal aortic reconstructi

69 Median cardiopulmonary bypass and aortic cross-clamp times were

70 high risk for complications associated with cardiopulmonary bypass and aortic manipulation.

71 ular stroke work index was examined prior to cardiopulmonary bypass and at 24 hours reperfusion.

72 opolysaccharide group but only at the end of cardiopulmonary bypass and beginning of postbypass (p <

73 ize the morbidity associated with the use of cardiopulmonary bypass and circulatory arrest in patient

74 Cardiac surgery, especially when employing cardiopulmonary bypass and deep hypothermic circulatory

75 ficant difference was found between low-flow cardiopulmonary bypass and deep hypothermic circulatory

76 th ischemia and reperfusion injury following cardiopulmonary bypass and deep hypothermic circulatory

77 f lung endothelial nitric oxide levels after cardiopulmonary bypass and deep hypothermic circulatory

78 inotropes, and RBC transfusion starting from cardiopulmonary bypass and ending 8 hours after arrival

79 ed for nonemergent cardiac surgery requiring cardiopulmonary bypass and had recognized risk factors f

80 xcellent, this technique requires the use of cardiopulmonary bypass and is associated with protracted

81 Generation of plasma hemoglobin during cardiopulmonary bypass and male gender are associated wi

82 thout cardiac arrest, followed by 60 mins of cardiopulmonary bypass and mechanical ventilation.

83 uggested that CABG techniques that eliminate cardiopulmonary bypass and reduce aortic manipulation ma

84 Here we investigated the effect of cardiopulmonary bypass and reperfusion on myocardial nit

85 ry to attenuate the inflammatory response to cardiopulmonary bypass and surgical trauma; however, evi

86 ified in the lipopolysaccharide group during cardiopulmonary bypass and the postbypass period (p < 0.

87 Levels of plasma hemoglobin increased during cardiopulmonary bypass and were associated (p < 0.01) wi

88 s between intervention (ie, after removal of cardiopulmonary bypass) and closure of chest.

89 line (in a subset), the beginning and end of cardiopulmonary bypass, and 2 hours and 24 hours after c

90 uits of heater-cooler units connected to the cardiopulmonary bypass, and air samples collected when t

91 tients, matched by age group, gender, use of cardiopulmonary bypass, and Hannan perioperative risk sc

92 ally harmful processes that are initiated by cardiopulmonary bypass, and how they may be attenuated.

93 have been introduced to minimize exposure to cardiopulmonary bypass, and improve outcomes for these h

94 ure, avoidance of the detrimental effects of cardiopulmonary bypass, and larger effective orifice are

95 re of injury, type of repair, utilization of cardiopulmonary bypass, and outcome.

96 of coronary artery disease, prolonged use of cardiopulmonary bypass, and severe primary graft dysfunc

97 Ten swine underwent a 90-minute cardiopulmonary bypass, and surveillance was maintained

98 bition of systemic inflammatory responses to cardiopulmonary bypass, and the treatment of shock state

99 , including cardiac surgery (with or without cardiopulmonary bypass), aortic surgery and renal revasc

100 Conventional MV surgery requires cardiopulmonary bypass, aortic cross-clamping, cardiople

101 and repair on an arrested heart, but require cardiopulmonary bypass, aortic cross-clamping, sternotom

102 and severity of the inflammatory response to cardiopulmonary bypass, as well as possible techniques f

103 We also showed that the use of cardiopulmonary bypass assistance may help alleviate som

104 igations were pursued: (1) identification of cardiopulmonary bypass-associated M. chimaera infection

105 Eighteen probable cases of cardiopulmonary bypass-associated M. chimaera infection

106 ive patients undergoing cardiac surgery with cardiopulmonary bypass at 12 hospitals from October 6, 2

107 ars or older undergoing cardiac surgery with cardiopulmonary bypass at 8 cardiac surgical centers in

108 n, the hepatic resection was performed under cardiopulmonary bypass because of extended vena cava thr

109 nd cooled to 16 degrees C to 18 degrees C on cardiopulmonary bypass before instituting deep hypotherm

110 ronary artery bypass graft-only surgery with cardiopulmonary bypass between August 2001 and May 2005.

111 04) rSo(2) during the 60-minute period after cardiopulmonary bypass but not with other perfusion phas

112 l concentration occurred during surgery with cardiopulmonary bypass but was no longer present after c

113 es cardiac output after cardiac surgery with cardiopulmonary bypass, but a detailed analysis of its e

114 he management of uncontrolled bleeding after cardiopulmonary bypass, but additional randomized, place

115 oronary artery bypass grafting surgery using cardiopulmonary bypass by 32 surgeons at 8 centers in no

116 Autoregulation was monitored during cardiopulmonary bypass by calculating a continuous, movi

117 thods of oxygenation and ventilation such as cardiopulmonary bypass can be used successfully to treat

118 ented with arterial and venous catheters and cardiopulmonary bypass cannulae) were randomized to conv

119 d by the Cockroft-Gault formula), undergoing cardiopulmonary bypass cardiac surgery.

120 with increased morbidity and mortality after cardiopulmonary bypass cardiac surgery.

121 patients with renal insufficiency undergoing cardiopulmonary bypass cardiac surgery.

122 oplegic arrest followed by reperfusion after cardiopulmonary bypass causes microvascular dysfunction

123 ocardial and peripheral tissues after CA and cardiopulmonary bypass (CBP).

124 Circulation of blood on the cardiopulmonary bypass circuit and the operative procedu

125 of this review is to present developments in cardiopulmonary bypass circuitry, and to give the author

126 have had surgery using the various forms of cardiopulmonary bypass circuitry.

127 ventive surgical strategies (PSS: peripheral cardiopulmonary bypass, circulatory arrest, and non-medi

128 There were 344 shunts placed without cardiopulmonary bypass (closed shunt), 287 shunts with b

129 ows, pressures, and hematocrit levels during cardiopulmonary bypass continue to create controversy.

130 Investigations into cardiopulmonary bypass continue to refine knowledge and

131 e coronary syndrome (ACS) patients requiring cardiopulmonary bypass (coronary artery bypass graft sur

132 Cardiopulmonary bypass-coronary artery bypass graft or d

133 cal dysfunction following reperfusion or the cardiopulmonary bypass-coronary artery bypass graft-indu

134 Cardioplegia and cardiopulmonary bypass (CP/CPB) leads to an increase in

135 Cardioplegia and cardiopulmonary bypass (CP/CPB) subjects myocardium to c

136 tive, cardiac surgery using cardioplegia and cardiopulmonary bypass (CP/CPB) subjects myocardium to h

137 vs 28 (27-30) points; P = 0.021], length of cardiopulmonary bypass (CPB) [CPB; 133 (112-163) vs 119

138 nt inhibitor of complement activation during cardiopulmonary bypass (CPB) has been shown to significa

139 ed before, during and after deep hypothermic cardiopulmonary bypass (CPB) in nine neonates.

140 y response triggered by cardiac surgery with cardiopulmonary bypass (CPB) is a primary mechanism in t

141 We investigated the effects of cardiopulmonary bypass (CPB) on peripheral arteriolar re

142 We investigated the effects of cardiopulmonary bypass (CPB) on the contractile response

143 Cardiopulmonary bypass (CPB) provokes inflammation culmi

144 ciated with cerebral hypoxia-ischemia during cardiopulmonary bypass (CPB) remains limited, largely du

145 ecognized immune response to protamine after cardiopulmonary bypass (CPB) surgery with potential impo

146 Data from 345 children after cardiopulmonary bypass (CPB) were analyzed.

147 sively generated during cardiac surgery with cardiopulmonary bypass (CPB), produces intravascular fib

148 reased in performing CABG without the use of cardiopulmonary bypass (CPB), to reduce postoperative co

149 ed to reverse heparin anticoagulation during cardiopulmonary bypass (CPB).

150 ht reduce systemic inflammation induced by a cardiopulmonary bypass (CPB).

151 ne (S(Cr)) is a delayed marker for AKI after cardiopulmonary bypass (CPB).

152 m of vasodilatory shock that can occur after cardiopulmonary bypass (CPB).

153 al coronary artery bypass grafting (CABG) on cardiopulmonary bypass (CPB).

154 coronary artery bypass grafting (CABG) using cardiopulmonary bypass (CPB).

155 h-risk females undergoing cardiac surgery on cardiopulmonary bypass (CPB).

156 20% to 40% of surgical procedures requiring cardiopulmonary bypass (CPB).

157 performing CABG both off-pump (OPCAB) and on cardiopulmonary bypass (CPB).

158 s undergoing cardiac surgery with the use of cardiopulmonary bypass (CPB).

159 Harvesting did not affect cardiopulmonary bypass, cross-clamp, or surgical times.

160 ent of specially designed internal emergency cardiopulmonary bypass devices.

161 average mean arterial blood pressure during cardiopulmonary bypass did not differ, the mean arterial

162 y bypass and were associated (p < 0.01) with cardiopulmonary bypass duration (R = 0.22), depletion of

163 te analysis, baseline cholesterol levels and cardiopulmonary bypass duration were significant and ind

164 lve mean pressure gradient <40 mm Hg, longer cardiopulmonary bypass duration, and prosthesis-patient

165 ndergoing primary isolated CABG surgery with cardiopulmonary bypass during calendar year 2008 at 798

166 rposition approach to liver transplantation, cardiopulmonary bypass during liver transplantation in t

167 seline), at cardiopulmonary bypass start, at cardiopulmonary bypass end, and 3 and 24 hours after car

168 h-risk patients undergoing CABG surgery with cardiopulmonary bypass enrolled between October 2006 and

169 cal approach, and in providing a timely post-cardiopulmonary bypass evaluation of the procedure, ther

170 ading dose of study drug was administered on cardiopulmonary bypass followed by a continuous infusion

171 R or N-EPR, resuscitation was initiated with cardiopulmonary bypass for 60 mins and mechanical ventil

172 tween ages 1 month to 18 years who underwent cardiopulmonary bypass for cardiac surgery and survived

173 ey injury in infants and children undergoing cardiopulmonary bypass for cardiac surgery.

174 pulmonary bypass and 4, 24, and 48 hrs after cardiopulmonary bypass for measurement of plasma arginin

175 tive intraaortic balloon pumps, or return to cardiopulmonary bypass (for hemodynamic reasons).

176 ents undergoing CABG surgery with or without cardiopulmonary bypass from February 1, 2002, through Ma

177 ts having coronary bypass graft surgery with cardiopulmonary bypass from November 1996 to June 2000 a

178 rtion (OR, 4.41; CI, 2.21 to 8.80; P<0.001), cardiopulmonary bypass >2 hours (OR, 1.78; CI, 1.15 to 2

179 acic surgery and a possible association with cardiopulmonary bypass heater-cooler units following ale

180 of reducing the inflammatory response after cardiopulmonary bypass; however, the value of this appro

181 ing hopes to avoid morbidity associated with cardiopulmonary bypass, improving clinical outcomes.

182 onary bypass, and 2 hours and 24 hours after cardiopulmonary bypass in 60 subjects.

183 ome patients with intractable bleeding after cardiopulmonary bypass in both pediatric and adult popul

184 rt has been implemented since the origins of cardiopulmonary bypass in the 1950s, but differs in seve

185 l improvements, including the development of cardiopulmonary bypass in the 1950s, large-scale repair

186 ronary-artery bypass grafting (CABG) without cardiopulmonary bypass in the elderly are still undeterm

187 among patients undergoing CABG surgery with cardiopulmonary bypass in US hospitals in an adult cardi

188 Changes in LV function at the conclusion of cardiopulmonary bypass included decreased stroke area (f

189 , but differs in several important ways from cardiopulmonary bypass, including its prolonged duration

190 an effort to prevent deleterious effects of cardiopulmonary bypass, including the associated inflamm

191 Systemic inflammation triggered by cardiopulmonary bypass increased plasma levels of the IF

192 tension or recipients who required prolonged cardiopulmonary bypass increased the risk for mortality.

193 ng coronary artery bypass graft surgery with cardiopulmonary bypass, increased atrial matrix metallop

194 indicates that immature WM is vulnerable to cardiopulmonary bypass-induced injury but has an intrins

195 eration was observed within a few days after cardiopulmonary bypass-induced ischemia-reperfusion inju

196 n this model, WM injury was identified after cardiopulmonary bypass-induced ischemia-reperfusion inju

197 ic arrest (CP) followed by reperfusion after cardiopulmonary bypass induces coronary microvascular dy

198 ardiogram, pulmonary artery catheterization, cardiopulmonary bypass, inhaled nitric oxide, and inhale

199 Cardiopulmonary bypass initiates a systemic inflammatory

200 ry bypass grafting performed with the use of cardiopulmonary bypass is a well-validated treatment for

201 tional coronary artery bypass grafting using cardiopulmonary bypass is an excellent treatment, howeve

202 Cardiac surgery with cardiopulmonary bypass is associated with mechanical man

203 surgical coronary revascularization without cardiopulmonary bypass is its lower hemorrhagic sequelae

204 ng coronary artery bypass graft surgery with cardiopulmonary bypass, it reduced cardiac matrix metall

205 ergoing coronary artery bypass grafting with cardiopulmonary bypass, levosimendan compared with place

206 After cardiac surgery with cardiopulmonary bypass, levosimendan induces a vasodilat

207 sed sterile water for heater-cooler units of cardiopulmonary bypass machines.

208 levels before elective cardiac surgery with cardiopulmonary bypass may be a simple biomarker for the

209 In addition, the elimination of cardiopulmonary bypass may reduce the risk of short-term

210 % CI, 5.1-68.4; p = 0.001) with earlier post-cardiopulmonary bypass measures of uncertain utility.

211 the possibility that mild hypothermia after cardiopulmonary bypass might be neuroprotective.

212 re being explored with the goals of avoiding cardiopulmonary bypass, minimizing disfiguring scars, an

213 extensive surgical procedures, avoidance of cardiopulmonary bypass, minimizing injury from radiocont

214 During initiation of cardiopulmonary bypass, MMP activity increased by 20% fr

215 of myocardial blood flow and separation from cardiopulmonary bypass, MMP interstitial activity increa

216 We developed a porcine cardiopulmonary bypass model that displays area-dependen

217 lower quartile (< 9.2 pg/mL) at 4 hrs after cardiopulmonary bypass (n = 29), labeled group A, were e

218 -thoracotomy with peripheral cannulation for cardiopulmonary bypass (n=3907) were analyzed.

219 less than 18 years old, procedures requiring cardiopulmonary bypass, no preexisting renal dysfunction

220 us circulation could not be restored without cardiopulmonary bypass; none survived.

221 imary outcome when measured 18-24 hours post-cardiopulmonary bypass (odds ratio, 18.6; 95% CI, 5.1-68

222 C transfusion during surgery and duration of cardiopulmonary bypass (odds ratio, 2.98; 95% CI, 1.96-4

223 cardiopulmonary bypass (on pump) or without cardiopulmonary bypass (off pump).

224 CABG without cardiopulmonary bypass (off-pump CABG) might reduce the

225 CABG to undergo the procedure either without cardiopulmonary bypass (off-pump CABG) or with it (on-pu

226 e effect of MR reduction without surgery and cardiopulmonary bypass on left ventricular (LV) dimensio

227 (CABG) surgery may be performed either with cardiopulmonary bypass (on pump) or without cardiopulmon

228 technique (off-pump CABG), as compared with cardiopulmonary bypass (on-pump CABG), are not clearly e

229 traditionally been performed with the use of cardiopulmonary bypass (on-pump CABG).

230 and those who underwent CABG performed with cardiopulmonary bypass (on-pump).

231 ry bypass grafting (CABG) without the use of cardiopulmonary bypass or cardioplegia (off-pump CABG, o

232 ement of patients requiring procedures using cardiopulmonary bypass or interventions in the catheteri

233 olytic drugs for use in cardiac surgery with cardiopulmonary bypass or organ transplantations to redu

234 olytic drugs for use in cardiac surgery with cardiopulmonary bypass or organ transplantations to redu

235 e use in the context of failure to wean from cardiopulmonary bypass or use to avoid cardiopulmonary b

236 (OR, 2; 95% CI, 1.2-3.3; P = 0.008); use of cardiopulmonary bypass (OR, 3.4; 95% CI, 2.2-5.3; P < 0.

237 thetic induction and 250 mg at initiation of cardiopulmonary bypass) or placebo.

238 y after transplant surgery performed without cardiopulmonary bypass (P for interaction = 0.03).

239 ts who underwent elective cardiac surgery on cardiopulmonary bypass, paired samples of the right atri

240 In patients undergoing cardiopulmonary bypass, plasma KIM-1 levels increased wi

241 near horizon is the combination of advanced cardiopulmonary bypass plus a cocktail of multiple agent

242 WMI was also associated with the duration of cardiopulmonary bypass, postoperative lactate level, bra

243 corporeal cardiopulmonary resuscitation with cardiopulmonary bypass potentially provides cerebral rep

244 -associated lipocalin measured 3 hours after cardiopulmonary bypass provided excellent early risk str

245 a cardiovascular surgeon, perfusionist, and cardiopulmonary bypass pump facilitates lifesaving repai

246 ion of haptoglobin at end and 24 hours after cardiopulmonary bypass (R = 0.12 and 0.15, respectively)

247 tively), lactate dehydrogenase levels at end cardiopulmonary bypass (R = 0.27), and change in creatin

248 T1 correlated with RV T1 (r=0.45, P<0.001), cardiopulmonary bypass (r=0.30, P=0.007), and aortic cro

249 In anaesthetized dogs connected to cardiopulmonary bypass, reflexogenic areas of the caroti

250 tively low at baseline and remains low after cardiopulmonary bypass regardless of hemodynamic stabili

251 ia-induced cardiac arrest followed by 30 min cardiopulmonary bypass resuscitation.

252 tive therapies such as cricothyroidotomy and cardiopulmonary bypass should be available if first-line

253 s before anesthesia induction (baseline), at cardiopulmonary bypass start, at cardiopulmonary bypass

254 in was 4.9 +/- 2.6 in group A at 4 hrs after cardiopulmonary bypass, statistically unchanged from its

255 Cardiopulmonary bypass surgery (CPB) is associated with

256 Of 591 patients undergoing cardiopulmonary bypass surgery, 57 (9.6%) tested positiv

257 a, such as that induced by cardiac arrest or cardiopulmonary bypass surgery, causes cell death in vul

258 RT/H antibodies occur in patients undergoing cardiopulmonary bypass surgery.

259 or acute insulin resistance associated with cardiopulmonary bypass surgery.

260 e 2 diabetes mellitus and patients following cardiopulmonary bypass surgery.

261 As operative and cardiopulmonary bypass techniques have evolved, early co

262 METHODS AND Under cardiopulmonary bypass, the papillary muscle tips in 6 a

263 Under cardiopulmonary bypass, the papillary muscle tips in 6 s

264 ts with congenital heart disease who undergo cardiopulmonary bypass, those who receive extracorporeal

265 = 2.4), hemodynamic instability (OR = 2.8), cardiopulmonary bypass time >120 minutes (OR = 6.2), per

266 ergency status (P=0.006), rupture (P=0.004), cardiopulmonary bypass time >120 minutes (P<0.04), and p

267 ood operation (HR, 2.3; P=0.001), and longer cardiopulmonary bypass time (HR, 1.1 per 10 minutes; P=0

268 Cardiopulmonary bypass time and age were independently a

269 A surgical strategy to minimize cardiopulmonary bypass time is critical for these challe

270 Cardiopulmonary bypass time may be a marker for case com

271 prised 72% of procedures and had a mean (SD) cardiopulmonary bypass time of 200 minutes (83) minutes.

272 In the CABG group, cardiopulmonary bypass time or days in intensive care di

273 Longer cardiopulmonary bypass time was linearly and independent

274 Cardiopulmonary bypass time was the only independent sur

275 analysis, age more than 65 years, prolonged cardiopulmonary bypass time, and severe pulmonary hypert

276 r resistance index, graft ischemic time, and cardiopulmonary bypass time, donor low-dose dopamine was

277 included pre-operative diuretic use, longer cardiopulmonary bypass time, operation prior to 1991, at

278 Piglets were cooled with cardiopulmonary bypass to 18 degrees C followed by deep

279 ve coronary artery bypass graft surgery with cardiopulmonary bypass to determine whether doxycycline

280 h the presentation, blood loss, and need for cardiopulmonary bypass to facilitate repair.

281 s undergoing cardiac surgery with the use of cardiopulmonary bypass to receive either methylprednisol

282 ntricular shape change device placed without cardiopulmonary bypass to reduce FMR.

283 duled for elective cardiac surgery requiring cardiopulmonary bypass under total anesthesia with intra

284 justing for pretransplantation lung disease, cardiopulmonary bypass use, and population stratificatio

285 of 31 patients (61%); the median duration of cardiopulmonary bypass was 19 minutes.

286 patients had a moderate or large injury, and cardiopulmonary bypass was required in 13 patients with

287 There were 34 patients in whom cardiopulmonary bypass was used (7.6%), 17 conversions t

288 Cardiopulmonary bypass was used for 19 of 31 patients (6

289 lack of mitral annuloplasty, and duration of cardiopulmonary bypass were associated with increased ri

290 ombined coronary artery bypass grafting with cardiopulmonary bypass were enrolled from June 2013 unti

291 gth of intensive care unit stay, and time on cardiopulmonary bypass were secondary outcomes.

292 ient >20 mm Hg) and prolonged intraoperative cardiopulmonary bypass were significant risk factors for

293 chemical pleurodesis procedure and prolonged cardiopulmonary bypass were significantly associated wit

294 autoregulation threshold (mm Hg x min/hr of cardiopulmonary bypass) were both higher in patients wit

295 ystemic inflammatory response to surgery and cardiopulmonary bypass, which in turn may mediate prolon

296 cases of aortic aneurysm repair, 7 involving cardiopulmonary bypass with deep hypothermic circulatory

297 These studies used emergency cardiopulmonary bypass with heat exchanger or a single h

298 ing antegrade cerebral perfusion, the use of cardiopulmonary bypass with mild hypothermia, and the in

299 cheduled for routine cardiac procedures with cardiopulmonary bypass without documented dementia were

300 c subgroups of pediatric patients undergoing cardiopulmonary bypass would benefit from potential trea